Recent Insights Into the Role of Autoimmunity in Idiopathic Dilated Cardiomyopathy

Journal of Cardiac Failure

Volumn 14, Issue 6, 2008, Pages 521-530

  Lappé, Jason M ^a   Pelfrey, Clara M ^a   Tang, W H Wilson ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Autoimmune; heart failure; immunoadsorption; inflammation; intravenous immunoglobulin

Indexed keywords

AZATHIOPRINE; BETA 1 ADRENERGIC RECEPTOR; ETANERCEPT; HLA ANTIGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; INFLIXIMAB; MYOSIN HEAVY CHAIN ALPHA; PENTOXIFYLLINE; PREDNISONE; THALIDOMIDE; TROPONIN I;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELLULAR IMMUNITY; CONGESTIVE CARDIOMYOPATHY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; GENETIC PREDISPOSITION; HUMAN; IMMUNOADSORPTION; IMMUNOMODULATION; INFLAMMATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; VIRUS INFECTION;

AUTOIMMUNE DISEASES; CARDIOMYOPATHY, DILATED; CLINICAL TRIALS AS TOPIC; HUMANS;

EID: 47949094210     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2008.02.016     Document Type: Review

References (74)

1. Maron B.J., Towbin J.A., Thiene G., Antzelevitch C., Corrado D., Arnett D., et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 113 (2006) 1807-1816
2. Sampietro T., Neglia D., Bionda A., Dal Pino B., Bigazzi F., Puntoni M., et al. Inflammatory markers and serum lipids in idiopathic dilated cardiomyopathy. Am J Cardiol 96 (2005) 1718-1720
3. Kuhl U., Noutsias M., Seeberg B., and Schultheiss H.P. Immunohistological evidence for a chronic intramyocardial inflammatory process in dilated cardiomyopathy. Heart 75 (1996) 295-300
4. Aretz H.T. Myocarditis: the Dallas criteria. Hum Pathol 18 (1987) 619-624
5. Liu P.P., and Mason J.W. Advances in the understanding of myocarditis. Circulation 104 (2001) 1076-1082
6. Kuhl U., Pauschinger M., Seeberg B., Lassner D., Noutsias M., Poller W., et al. Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation 112 (2005) 1965-1970
7. Kuhl U., Pauschinger M., Schwimmbeck P.L., Seeberg B., Lober C., Noutsias M., et al. Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation 107 (2003) 2793-2798
8. Woolf A.D., Campion G.V., Chishick A., Wise S., Cohen B.J., Klouda P.T., et al. Clinical manifestations of human parvovirus B19 in adults. Arch Intern Med 149 (1989) 1153-1156
9. Okuno T., Takahashi K., Balachandra K., Shiraki K., Yamanishi K., Takahashi M., et al. Seroepidemiology of human herpesvirus 6 infection in normal children and adults. J Clin Microbiol 27 (1989) 651-653
10. Lotze U., Egerer R., Tresselt C., Gluck B., Dannberg G., Stelzner A., et al. Frequent detection of parvovirus B19 genome in the myocardium of adult patients with idiopathic dilated cardiomyopathy. Med Microbiol Immunol 193 (2004) 75-82
11. Kuethe F., Sigusch H.H., Hilbig K., Tresselt C., Gluck B., Egerer R., et al. Detection of viral genome in the myocardium: lack of prognostic and functional relevance in patients with acute dilated cardiomyopathy. Am Heart J 153 (2007) 850-858
12. Kyvik K.O., Green A., and Beck-Nielsen H. Concordance rates of insulin dependent diabetes mellitus: a population based study of young Danish twins. BMJ 311 (1995) 913-917
13. Willer C.J., Dyment D.A., Risch N.J., Sadovnick A.D., and Ebers G.C. Twin concordance and sibling recurrence rates in multiple sclerosis. Proc Natl Acad Sci U S A 100 (2003) 12877-12882
14. Michels V.V., Moll P.P., Miller F.A., Tajik A.J., Chu J.S., Driscoll D.J., et al. The frequency of familial dilated cardiomyopathy in a series of patients with idiopathic dilated cardiomyopathy. N Engl J Med 326 (1992) 77-82
15. Limas C.J., Iakovis P., Anyfantakis A., Kroupis C., and Cokkinos D.V. Familial clustering of autoimmune diseases in patients with dilated cardiomyopathy. Am J Cardiol 93 (2004) 1189-1191
16. Carlquist J.F., Menlove R.L., Murray M.B., O'Connell J.B., and Anderson J.L. HLA class II (DR and DQ) antigen associations in idiopathic dilated cardiomyopathy. Validation study and meta-analysis of published HLA association studies. Circulation 83 (1991) 515-522
17. McKenna C.J., Codd M.B., McCann H.A., and Sugrue D.D. Idiopathic dilated cardiomyopathy: familial prevalence and HLA distribution. Heart 77 (1997) 549-552
18. Baba A., Yoshikawa T., and Ogawa S. Autoantibodies produced against sarcolemmal Na-K-ATPase: possible upstream targets of arrhythmias and sudden death in patients with dilated cardiomyopathy. J Am Coll Cardiol 40 (2002) 1153-1159
19. Konstadoulakis M.M., Kroumbouzou H., Tsiamis E., Trikas A., and Toutouzas P. Clinical significance of antibodies against tropomyosin, actin and myosin in patients with dilated cardiomyopathy. J Clin Lab Immunol 40 (1993) 61-67
20. Stork S., Boivin V., Horf R., Hein L., Lohse M.J., Angermann C.E., et al. Stimulating autoantibodies directed against the cardiac beta1-adrenergic receptor predict increased mortality in idiopathic cardiomyopathy. Am Heart J 152 (2006) 697-704
21. Baba A., Yoshikawa T., Fukuda Y., Sugiyama T., Shimada M., Akaishi M., et al. Autoantibodies against M2-muscarinic acetylcholine receptors: new upstream targets in atrial fibrillation in patients with dilated cardiomyopathy. Eur Heart J 25 (2004) 1108-1115
22. Lauer B., Schannwell M., Kuhl U., Strauer B.E., and Schultheiss H.P. Antimyosin autoantibodies are associated with deterioration of systolic and diastolic left ventricular function in patients with chronic myocarditis. J Am Coll Cardiol 35 (2000) 11-18
23. Muller J., Wallukat G., Dandel M., Bieda H., Brandes K., Spiegelsberger S., et al. Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. Circulation 101 (2000) 385-391
24. Cunningham M.W., Hall N.K., Krisher K.K., and Spanier A.M. A study of anti-group A streptococcal monoclonal antibodies cross-reactive with myosin. J Immunol 136 (1986) 293-298
25. Alvarez F.L., Neu N., Rose N.R., Craig S.W., and Beisel K.W. Heart-specific autoantibodies induced by Coxsackievirus B3: identification of heart autoantigens. Clin Immunol Immunopathol 43 (1987) 129-139
26. Galvin J.E., Hemric M.E., Kosanke S.D., Factor S.M., Quinn A., and Cunningham M.W. Induction of myocarditis and valvulitis in lewis rats by different epitopes of cardiac myosin and its implications in rheumatic carditis. Am J Pathol 160 (2002) 297-306
27. Caforio A.L., Grazzini M., Mann J.M., Keeling P.J., Bottazzo G.F., McKenna W.J., et al. Identification of alpha- and beta-cardiac myosin heavy chain isoforms as major autoantigens in dilated cardiomyopathy. Circulation 85 (1992) 1734-1742
28. Dangas G., Konstadoulakis M.M., Epstein S.E., Stefanadis C.I., Kymionis G.D., Toutouza M.G., et al. Prevalence of autoantibodies against contractile proteins in coronary artery disease and their clinical implications. Am J Cardiol 85 (2000) 870-872 A6, A9
29. Li Y., Heuser J.S., Cunningham L.C., Kosanke S.D., and Cunningham M.W. Mimicry and antibody-mediated cell signaling in autoimmune myocarditis. J Immunol 177 (2006) 8234-8240
30. Staudt Y., Mobini R., Fu M., Felix S.B., Kuhn J.P., and Staudt A. Beta1-adrenoceptor antibodies induce apoptosis in adult isolated cardiomyocytes. Eur J Pharmacol 466 (2003) 1-6
31. Ferrari I., Levin M.J., Wallukat G., Elies R., Lebesgue D., Chiale P., et al. Molecular mimicry between the immunodominant ribosomal protein P0 of Trypanosoma cruzi and a functional epitope on the human beta 1-adrenergic receptor. J Exp Med 182 (1995) 59-65
32. Jahns R., Boivin V., Krapf T., Wallukat G., Boege F., and Lohse M.J. Modulation of beta1-adrenoceptor activity by domain-specific antibodies and heart failure-associated autoantibodies. J Am Coll Cardiol 36 (2000) 1280-1287
33. Wallukat G., Wollenberger A., Morwinski R., and Pitschner H.F. Anti-beta 1-adrenoceptor autoantibodies with chronotropic activity from the serum of patients with dilated cardiomyopathy: mapping of epitopes in the first and second extracellular loops. J Mol Cell Cardiol 27 (1995) 397-406
34. Christ T., Wettwer E., Dobrev D., Adolph E., Knaut M., Wallukat G., et al. Autoantibodies against the beta1 adrenoceptor from patients with dilated cardiomyopathy prolong action potential duration and enhance contractility in isolated cardiomyocytes. J Mol Cell Cardiol 33 (2001) 1515-1525
35. Jahns R., Boivin V., Hein L., Triebel S., Angermann C.E., Ertl G., et al. Direct evidence for a beta 1-adrenergic receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy. J Clin Invest 113 (2004) 1419-1429
36. Mobini R., Staudt A., Felix S.B., Baumann G., Wallukat G., Deinum J., et al. Hemodynamic improvement and removal of autoantibodies against beta1-adrenergic receptor by immunoadsorption therapy in dilated cardiomyopathy. J Autoimmun 20 (2003) 345-350
37. Jahns R., Boivin V., Siegmund C., Inselmann G., Lohse M.J., and Boege F. Autoantibodies activating human beta1-adrenergic receptors are associated with reduced cardiac function in chronic heart failure. Circulation 99 (1999) 649-654
38. Miao G.B., Liu J.C., Liu M.B., Wu J.L., Zhang G., Chang J., et al. Autoantibody against beta1-adrenergic receptor and left ventricular remodeling changes in response to metoprolol treatment. Eur J Clin Invest 36 (2006) 614-620
39. Iwata M., Yoshikawa T., Baba A., Anzai T., Mitamura H., and Ogawa S. Autoantibodies against the second extracellular loop of beta1-adrenergic receptors predict ventricular tachycardia and sudden death in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 37 (2001) 418-424
40. Horwich T.B., Patel J., MacLellan W.R., and Fonarow G.C. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation 108 (2003) 833-838
41. Goser S., Andrassy M., Buss S.J., Leuschner F., Volz C.H., Ottl R., et al. Cardiac troponin I but not cardiac troponin T induces severe autoimmune inflammation in the myocardium. Circulation 114 (2006) 1693-1702
42. Okazaki T., Tanaka Y., Nishio R., Mitsuiye T., Mizoguchi A., Wang J., et al. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med 9 (2003) 1477-1483
43. Shmilovich H., Danon A., Binah O., Roth A., Chen G., Wexler D., et al. Autoantibodies to cardiac troponin I in patients with idiopathic dilated and ischemic cardiomyopathy. Int J Cardiol 117 (2007) 198-203
44. Noutsias M., Pauschinger M., Schultheiss H., and Kh U. Phenotypic characterization of infiltrates in dilated cardiomyopathy-diagnostic significance of T-lymphocytes and macrophages in inflammatory cardiomyopathy. Med Sci Monit 8 (2002) CR478-CR487
45. Omerovic E., Bollano E., Andersson B., Kujacic V., Schulze W., Hjalmarson A., et al. Induction of cardiomyopathy in severe combined immunodeficiency mice by transfer of lymphocytes from patients with idiopathic dilated cardiomyopathy. Autoimmunity 32 (2000) 271-280
46. Lunardi C., Tiso M., Borgato L., Nanni L., Millo R., De Sandre G., et al. Chronic parvovirus B19 infection induces the production of anti-virus antibodies with autoantigen binding properties. Eur J Immunol 28 (1998) 936-948
47. Wucherpfennig K.W., and Strominger J.L. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 80 (1995) 695-705
48. Lapierre P., Beland K., and Alvarez F. Pathogenesis of autoimmune hepatitis: from break of tolerance to immune-mediated hepatocyte apoptosis. Transl Res 149 (2007) 107-113
49. Hughes R.A., Allen D., Makowska A., and Gregson N.A. Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst 11 (2006) 30-46
50. Mann D.L., McMurray J.J., Packer M., Swedberg K., Borer J.S., Colucci W.S., et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109 (2004) 1594-1602
51. Parrillo J.E., Cunnion R.E., Epstein S.E., Parker M.M., Suffredini A.F., Brenner M., et al. A prospective, randomized, controlled trial of prednisone for dilated cardiomyopathy. N Engl J Med 321 (1989) 1061-1068
52. Wojnicz R., Nowalany-Kozielska E., Wojciechowska C., Glanowska G., Wilczewski P., Niklewski T., et al. Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two-year follow-up results. Circulation 104 (2001) 39-45
53. Gullestad L., Ueland T., Fjeld J.G., Holt E., Gundersen T., Breivik K., et al. Effect of thalidomide on cardiac remodeling in chronic heart failure: results of a double-blind, placebo-controlled study. Circulation 112 (2005) 3408-3414
54. Chung E.S., Packer M., Lo K.H., Fasanmade A.A., and Willerson J.T. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107 (2003) 3133-3140
55. Skudicky D., Bergemann A., Sliwa K., Candy G., and Sareli P. Beneficial effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitors and carvedilol: results of a randomized study. Circulation 103 (2001) 1083-1088
56. Gullestad L., Semb A.G., Holt E., Skardal R., Ueland T., Yndestad A., et al. Effect of thalidomide in patients with chronic heart failure. Am Heart J 144 (2002) 847-850
57. Torre-Amione G., Bourge R.C., Colucci W.S., Greenberg B., Pratt C., Rouleau J.L., et al. A study to assess the effects of a broad-spectrum immune modulatory therapy on mortality and morbidity in patients with chronic heart failure: the ACCLAIM trial rationale and design. Can J Cardiol 23 (2007) 369-376
58. Kjekshus J., Apetrei E., Barrios V., Bohm M., Cleland J.G., Cornel J.H., et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 357 (2007) 2248-2261
59. Dorffel W.V., Felix S.B., Wallukat G., Brehme S., Bestvater K., Hofmann T., et al. Short-term hemodynamic effects of immunoadsorption in dilated cardiomyopathy. Circulation 95 (1997) 1994-1997
60. Felix S.B., Staudt A., Dorffel W.V., Stangl V., Merkel K., Pohl M., et al. Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy: three-month results from a randomized study. J Am Coll Cardiol 35 (2000) 1590-1598
61. Felix S.B., Staudt A., Landsberger M., Grosse Y., Stangl V., Spielhagen T., et al. Removal of cardiodepressant antibodies in dilated cardiomyopathy by immunoadsorption. J Am Coll Cardiol 39 (2002) 646-652
62. Wallukat G., Muller J., and Hetzer R. Specific removal of beta1-adrenergic autoantibodies from patients with idiopathic dilated cardiomyopathy. N Engl J Med 347 (2002) 1806
63. Schimke I., Muller J., Priem F., Kruse I., Schon B., Stein J., et al. Decreased oxidative stress in patients with idiopathic dilated cardiomyopathy one year after immunoglobulin adsorption. J Am Coll Cardiol 38 (2001) 178-183
64. Staudt A., Dorr M., Staudt Y., Bohm M., Probst M., Empen K., et al. Role of immunoglobulin G3 subclass in dilated cardiomyopathy: results from protein A immunoadsorption. Am Heart J 150 (2005) 729-736
65. Cooper L.T., Belohlavek M., Korinek J., Yoshifuku S., Sengupta P.P., Burgstaler E.A., et al. A pilot study to assess the use of protein a immunoadsorption for chronic dilated cardiomyopathy. J Clin Apher 22 (2007) 210-214
66. Staudt A., Hummel A., Ruppert J., Dorr M., Trimpert C., Birkenmeier K., et al. Immunoadsorption in dilated cardiomyopathy: 6-month results from a randomized study. Am Heart J 152 (2006) 712.e1-6
67. Dorner A., Kallwellis-Opara A., Pauschinger M., Kuhl U., and Schultheiss H. Cardiac autoantibodies in viral myocarditis. Heart Fail Clin 1 (2005) 333-343
68. van der Meche F.G., and Schmitz P.I. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. Dutch Guillain-Barre Study Group. N Engl J Med 326 (1992) 1123-1129
69. Gullestad L., Aass H., Fjeld J.G., Wikeby L., Andreassen A.K., Ihlen H., et al. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation 103 (2001) 220-225
70. McNamara D.M., Holubkov R., Starling R.C., Dec G.W., Loh E., Torre-Amione G., et al. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation 103 (2001) 2254-2259
71. McNamara D.M., Rosenblum W.D., Janosko K.M., Trost M.K., Villaneuva F.S., Demetris A.J., et al. Intravenous immune globulin in the therapy of myocarditis and acute cardiomyopathy. Circulation 95 (1997) 2476-2478
72. Kishimoto C., Shioji K., Kinoshita M., Iwase T., Tamaki S., Fujii M., et al. Treatment of acute inflammatory cardiomyopathy with intravenous immunoglobulin ameliorates left ventricular function associated with suppression of inflammatory cytokines and decreased oxidative stress. Int J Cardiol 91 (2003) 173-178
73. Drucker N.A., Colan S.D., Lewis A.B., Beiser A.S., Wessel D.L., Takahashi M., et al. Gamma-globulin treatment of acute myocarditis in the pediatric population. Circulation 89 (1994) 252-257
74. Caforio A.L., Mahon N.G., Baig M.K., Tona F., Murphy R.T., Elliott P.M., et al. Prospective familial assessment in dilated cardiomyopathy: cardiac autoantibodies predict disease development in asymptomatic relatives. Circulation 115 (2007) 76-83